TG Therapeutics TGTX Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's operating lease right-of-use asset amortization?
- TG Therapeutics (TGTX) reported operating lease right-of-use asset amortization of $573K in Q1 2026.
- How has TG Therapeutics's operating lease right-of-use asset amortization changed year-over-year?
- TG Therapeutics's operating lease right-of-use asset amortization increased by 26.5% year-over-year, from $453K to $573K.
- What is the long-term trend for TG Therapeutics's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), TG Therapeutics's operating lease right-of-use asset amortization has grown at a -2.0% compound annual growth rate (CAGR), from $1.9M to $1.75M.